Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2998-3002

  Chiu, Hao Chieh ^a   Yang, Jian ^a   Soni, Shilpa ^a   Kulp, Samuel K ^a   Gunn, John S ^a   Schlesinger, Larry S ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG STRUCTURE; FRANCISELLA TULARENSIS; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TULAREMIA;

ANIMALS; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; FRANCISELLA TULARENSIS; HUMANS; LACTONES; MICE; MICROBIAL SENSITIVITY TESTS; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 67649997355     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00048-09     Document Type: Article

References (24)

1. Alibek, K. 1999. Biohazard. Random House, New York, NY.
2. Clemens, D. L., B. Y. Lee, and M. A. Horwitz. 2004. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun. 72:3204-3217.
3. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lillibridge, J. E. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763-2773.
4. Edmondson, J. M., L. S. Armstrong, and A. O. Martinez. 1988. A rapid and simple MTT-based spectrophotometric assay for determining drug sensitivity in monolayer cultures. Methods Cell Sci. 11:15-17.
5. Ellis, J., P. C. Oyston, M. Green, and R. W. Titball. 2002. Tularemia. Clin. Microbiol. Rev. 15:631-646.
6. Golovliov, I., V. Baranov, Z. Krocova, H. Kovarova, and A. Sjostedt. 2003. An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect. Immun. 71:5940-5950.
7. Irache, J. M., H. H. Salman, C. Gamazo, and S. Espuelas. 2008. Mannosetargeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5:703-724.
8. Jerwood, S., and J. Cohen. 2008. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother. 61:362-364.
9. Kruszewska, H., T. Zareba, and S. Tyski. 2000. Antimicrobial activity of selected non-antibiotics-activity of methotrexate against Staphylococcus aureus strains. Acta Pol. Pharm. 57(Suppl.):117-119.
10. Kruszewska, H., T. Zareba, and S. Tyski. 2006. Estimation of antimicrobial activity of selected non-antibiotic products. Acta Pol. Pharm. 63:457-460.
11. Kruszewska, H., T. Zareba, and S. Tyski. 2004. Examination of antimicrobial activity of selected non-antibiotic drugs. Acta Pol. Pharm. 61(Suppl.):18-21.
12. Kruszewska, H., T. Zareba, and S. Tyski. 2002. Search of antimicrobial activity of selected non-antibiotic drugs. Acta Pol. Pharm. 59:436-439.
13. Lai, X. H., I. Golovliov, and A. Sjostedt. 2001. Francisella tularensis induces cytopathogenicity and apoptosis in murine macrophages via a mechanism that requires intracellular bacterial multiplication. Infect. Immun. 69:4691-4694.
14. Mariathasan, S., D. S. Weiss, V. M. Dixit, and D. M. Monack. 2005. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J. Exp. Med. 202:1043-1049.
15. Mohapatra, N. P., A. Balagopal, S. Soni, L. S. Schlesinger, and J. S. Gunn. 2007. AcpA is a Francisella acid phosphatase that affects intramacrophage survival and virulence. Infect. Immun. 75:390-396.
16. Mohapatra, N. P., S. Soni, T. J. Reilly, J. Liu, K. E. Klose, and J. S. Gunn. 2008. Combined deletion of four Francisella novicida acid phosphatases attenuates virulence and macrophage vacuolar escape. Infect. Immun. 76: 3690-3699.
17. Oyston, P. C. 2008. Francisella tularensis: unravelling the secrets of an intracellular pathogen. J. Med. Microbiol. 57:921-930.
18. Oyston, P. C., A. Sjostedt, and R. W. Titball. 2004. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2:967-978.
19. Prasit, P., Z. Wang, C. Brideau, C. C. Chan, S. Charleson, W. Cromlish, D. Ethier, J. F. Evans, A. W. Ford-Hutchinson, J. Y. Gauthier, R. Gordon, J. Guay, M. Gresser, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G. P. O'Neill, M. Ouellet, M. D. Percival, H. Perrier, D. Riendeau, I. Rodger, R. Zamboni, et al. 1999. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4́-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg. Med. Chem. Lett. 9:1773-1778.
20. Santic, M., R. Asare, I. Skrobonja, S. Jones, and Y. Abu Kwaik. 2008. Acquisition of the vacuolar ATPase proton pump and phagosome acidification are essential for escape of Francisella tularensis into the macrophage cytosol. Infect. Immun. 76:2671-2677.
21. Schonthal, A. H. 2007. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 97:1465-1468.
22. Sjostedt, A. 2003. Virulence determinants and protective antigens of Francisella tularensis. Curr. Opin. Microbiol. 6:66-71.
23. Tacconelli, S., M. L. Capone, M. G. Sciulli, E. Ricciotti, and P. Patrignani. 2002. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr. Med. Res. Opin. 18:503-511.
24. Wikler, M. A. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.